Numerous studies are offering novel medications for patients with breast cancer and reporting improvements in survival. Although the trials are well-described, at least 50% of patients are excluded because they are limited to those under 65 and free of co- morbidities. Even though there have been a ton of publications over the past two decades detailing how new chemicals are enhancing survival, the influence on Relative Survival (RS) has not been seen. Examining closely, the rise in Cardiovascular Deaths (CVDs) among people over 65 may be the cause. This reaffirms that additional non- cancer-related factors should be considered, as breast cancer is not the sole factor that affects patient outcomes. It is increasingly evident that patients with co-morbidities ought to be enrolled in clinical trials and/or that patients on those new medications need to be regularly watched, both of which raise the expense